Continuous manufacturing techniques are not new. Back in the days of the Industrial Revolution they allowed products such as paper to be made more quickly and in larger quantities. Although the concept made inroads into the oil refining and chemical manufacturing space more than 100 years ago, it only started to be genuinely explored in the pharmaceutical sector around the turn of this century. Starting off in academic research laboratories, the idea was gradually assimilated by R&D groups in some of the larger pharmaceutical companies, and momentum is continually building. The first example of a drug product made via continuous manufacturing was in 2015, when the U.S. FDA gave the go-ahead to Vertex’s cystic fibrosis combination drug, Orkambi (lumacaftor/ivacaftor). Janssen was not far behind, with the approval of HIV drug Prezista (darunavir) in 2016. Both companies have made significant investments in production lines dedicated to the manufacture of these final drug products. Click Here For Complete Abstract Text
|
||||||||||||||||||
| Application Sequencing | ||||||||||||||||||
|
||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | |||||||||
|
|
|
|
|
|
|
||||||||||||